Rapid exacerbation of neuromyelitis optica after rituximab treatment.
J Clin Neurosci. 2015 Dec 15;
Authors: Dai Y, Lu T, Wang Y, Fang L, Li R, Kermode AG, Qiu W
Abstract
Studies have shown the efficacy of immunosuppressants against neuromyelitis optica (NMO). Rituximab is recommended as an off-label prescription to treat refractory NMO. However, we describe two such patients who were suboptimally responsive to rituximab and whose symptoms worsened after treatment. Our cautionary cases highlight that in a small proportion of patients with refractory NMO, rituximab may either fail or induce rapid relapse of NMO. This suggests we need to consider new treatment strategies for refractory NMO.
PMID: 26704780 [PubMed - as supplied by publisher]
from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/1NGJzkE
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου